Suprachoroidal triamcinolone versus posterior subtenon triamcinolone either alone or formulated in the management of diabetic macular edema.
Diabetes mellitus (DM)
Diabetic macular edema (DME)
Diabetic retinopathy (DR)
Triamcinolone acetonide (TA)
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
12 Sep 2023
12 Sep 2023
Historique:
received:
29
07
2022
accepted:
05
08
2023
medline:
12
9
2023
pubmed:
12
9
2023
entrez:
12
9
2023
Statut:
aheadofprint
Résumé
This study aims to compare posterior subtenon triamcinolone acetonide injection either formulated or alone versus suprachoroidal triamcinolone in the management of diabetic macular edema. This study is a prospective interventional study that included 75 patients, divided into three groups, each group with 25 patients. Group I received a combination of triamcinolone acetonide (TA) (40 mg) and VISCOAT, which is a combination of sodium chondroitin sulfate (20 mg) and sodium hyaluronate (15 mg). The injection was done in the posterior subtenon space using the NAGATA cannula. Group II received TA (40 mg) in the posterior subtenon space. Group III underwent an injection of 4 mg/100µl of TA in the supra choroidal space. We found a statistically significant difference between the three studied groups regarding BCVA (P = 0.001) and CMT at six months postoperative (P = 0.001) with the highest median BCVA and lowest median CMT observed in the formulated TA group. We concluded that early treatment of DME by formulated TA is better than TA alone, and suprachoroidal TA in the form of increasing the BCVA and decreasing the CMT without any elevation of IOP. Trial registration number NCT05464953. Date of registration 17/7/2022 (retrospectively registered).
Identifiants
pubmed: 37698662
doi: 10.1007/s10792-023-02856-2
pii: 10.1007/s10792-023-02856-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Wang W, Lo ACY (2018) Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. https://doi.org/10.3390/ijms19061816
doi: 10.3390/ijms19061816
pubmed: 30597963
pmcid: 6337580
Danek D, Larsen B, Anderson-Nelson S (2021) Non-proliferative diabetic retinopathy. Dis Mon 67:101139. https://doi.org/10.1016/j.disamonth.2021.101139
doi: 10.1016/j.disamonth.2021.101139
pubmed: 33541706
Nentwich MM (2015) Diabetic retinopathy-ocular complications of diabetes mellitus. World J Diabetes 6:489. https://doi.org/10.4239/wjd.v6.i3.489
doi: 10.4239/wjd.v6.i3.489
pubmed: 25897358
pmcid: 4398904
Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A et al (2016) Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016:1–17. https://doi.org/10.1155/2016/2156273
doi: 10.1155/2016/2156273
Costa JV, Moura-Coelho N, Abreu AC et al (2021) Macular edema secondary to retinal vein occlusion in a real-life setting: a multicenter, nationwide, 3-year follow-up study. Graefe’s Arch Clin Exp Ophthalmol 259:343–350. https://doi.org/10.1007/s00417-020-04932-0
doi: 10.1007/s00417-020-04932-0
Elman MJ, Aiello LP, Beck RW et al (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:1064-1077.e35. https://doi.org/10.1016/j.ophtha.2010.02.031
doi: 10.1016/j.ophtha.2010.02.031
pubmed: 20427088
Bressler SB, Ayala AR, Bressler NM et al (2016) Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol 134:278. https://doi.org/10.1001/jamaophthalmol.2015.5346
doi: 10.1001/jamaophthalmol.2015.5346
pubmed: 26746868
pmcid: 4786449
Fossum P, Couret C, Briend B et al (2018) Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases. Eye 32:830–832. https://doi.org/10.1038/eye.2017.305
doi: 10.1038/eye.2017.305
pubmed: 29350689
pmcid: 5898875
Zhao M, Zhang C, Chen XM et al (2020) Comparison of intravitreal injection of conbercept and triamcinolone acetonide for macular edema secondary to branch retinal vein occlusion. Int J Ophthalmol 13:1765–1772. https://doi.org/10.18240/ijo.2020.11.13
doi: 10.18240/ijo.2020.11.13
pubmed: 33215008
pmcid: 7590870
Soo Geun J, Moon H, Chae J (2013) The effect of posterior subtenon injection of triamcinolone acetonide for diabetic macular edema refractory to intravitreal bevacizumab injection. Acta Ophthalmol. https://doi.org/10.1111/j.1755-3768.2013.3468.x
doi: 10.1111/j.1755-3768.2013.3468.x
Saleh MA, Abdelmoneim M, Fahmy H et al (2017) Posterior subtenon versus intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. J Curr Med Res Pract 2:141. https://doi.org/10.4103/JCMRP.JCMRP_29_16
doi: 10.4103/JCMRP.JCMRP_29_16
Tayyab H, Ahmed CN, Sadiq MAA (2019) Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema. Pak J Med Sci. https://doi.org/10.12669/pjms.36.2.1194
doi: 10.12669/pjms.36.2.1194
pubmed: 31086507
pmcid: 6500808
Veritti D, Lanzetta P, Perissin L, Bandello F (2009) Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up. Investig Opthalmol Vis Sci 50:2391. https://doi.org/10.1167/iovs.08-2518
doi: 10.1167/iovs.08-2518
McAllister IL, Vijayasekaran S, Chen SD, Yu D-Y (2009) Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 147:838-846.e2. https://doi.org/10.1016/j.ajo.2008.12.006
doi: 10.1016/j.ajo.2008.12.006
pubmed: 19211093
Becerra EM, Morescalchi F, Gandolfo F et al (2011) Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets 12:149–172. https://doi.org/10.2174/138945011794182746
doi: 10.2174/138945011794182746
pubmed: 20887246
Acharya P (2020) Posterior subtenon injection of triamcinolone (PSTT) for macular edema in various retinal conditions. Int J Ophthalmol Eye Sci. https://doi.org/10.19070/2332-290X-2000087
doi: 10.19070/2332-290X-2000087